Literature DB >> 18038228

Rule-based standardised switching of drugs at the interface between primary and tertiary care.

Stefanie U Walk1, Thilo Bertsche, Jens Kaltschmidt, Markus G Pruszydlo, Torsten Hoppe-Tichy, Ingeborg Walter-Sack I, Walter E Haefeli.   

Abstract

INTRODUCTION: Changes in drug treatment are frequently mandatory with hospital admission and discharge because hospital drug formularies are generally restricted to about 3000 drugs as compared to the many times this number - 62,000 in Germany - that are commercially available. Without computerised support, the process involved with switching drugs to a corresponding generic or a therapeutic equivalent is time-consuming and error-prone.
METHODS: We have developed and tested a standardised interchange algorithm for subsequent implementation into a computerised decision support system that switches drugs to the corresponding generic or a therapeutic equivalent if they are not listed on the hospital drug formulary.
RESULTS: The algorithm was retrospectively applied to the medication regimens of 120 patients (774 prescribed drugs containing 886 active ingredients) at their time of admission to surgical wards. Of the prescribed drugs, 52.8% (409/774) were part of the hospital drug formulary, thereby rendering a switch unnecessary. The 365 drugs not listed consisted of 392 active ingredients that were successfully switched to a corresponding generic (84.7%) or a therapeutic equivalent (10.2%). No specific switching procedures were defined for only 2.3% (20/886) of the active ingredients. In these cases, the drugs were either discontinued (4/20) or special drug classes, current diseases or co-medication required manual switching (8/20), or the drugs were continued unchanged and ordered from a wholesaler (8/20).
CONCLUSION: Using a standardised interchange algorithm, pre-admission drug regimens can successfully be switched to drugs on a hospital drug formulary. These findings suggest that a computerised decision support system will likely be useful to support this important practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18038228     DOI: 10.1007/s00228-007-0402-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

Review 1.  Therapeutic substitution: guilty until proven innocent.

Authors:  Dean J Kereiakes; James T Willerson
Journal:  Circulation       Date:  2003-11-25       Impact factor: 29.690

2.  Formulary management: antibiotics and therapeutic interchange.

Authors:  F Massoomi
Journal:  Pharm Pract Manag Q       Date:  1996-10

3.  [Short practice guideline for the management of gastroesophageal reflux disease].

Authors:  C Fibbe; J Keller; P Layer
Journal:  Dtsch Med Wochenschr       Date:  2005-08-26       Impact factor: 0.628

4.  Guidelines for therapeutic interchange-2004.

Authors:  Thomas Gray; Karen Bertch; Kimberly Galt; Michael Gonyeau; Emilie Karpiuk; Lance Oyen; Mary Jane Sudekum; Lee C Vermeulen
Journal:  Pharmacotherapy       Date:  2005-11       Impact factor: 4.705

5.  Are all angiotensin-converting enzyme inhibitors interchangeable?

Authors:  C D Furberg; B Pitt
Journal:  J Am Coll Cardiol       Date:  2001-04       Impact factor: 24.094

6.  Nonformulary drug requests at an academic hospital in Germany--the role of general practitioners' long-term medication.

Authors:  W Himmel; B Lönker; M M Kochen
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

7.  A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.

Authors:  B Djavan; M Marberger
Journal:  Eur Urol       Date:  1999       Impact factor: 20.096

Review 8.  Angiotensin II receptor antagonists.

Authors:  M Burnier; H R Brunner
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

9.  Bioequivalence and other unresolved issues in generic drug substitution.

Authors:  Peter Meredith
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

10.  Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors.

Authors:  Karen A Grace; Jennifer Swiecki; Richard Hyatt; Henry Gibbs; David L Jones; Munazza Sheikh; John Spain; Kent W Maneval; Rebecca Viola; Allen J Taylor
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

View more
  6 in total

1.  Structure and procedures of the pharmacy and therapeutic committees in Spanish hospitals.

Authors:  Francesc Puigventós; Bernardo Santos-Ramos; Ana Ortega; Esther Durán-García
Journal:  Pharm World Sci       Date:  2010-09-07

2.  Development and evaluation of an algorithm to facilitate drug prescription for inpatients with feeding tubes.

Authors:  Kristina Lohmann; Julia Freigofas; Julian Leichsenring; Chantal Marie Wallenwein; Walter Emil Haefeli; Hanna Marita Seidling
Journal:  Eur J Clin Pharmacol       Date:  2015-02-19       Impact factor: 2.953

3.  Systematic literature review of the methodology for developing pharmacotherapeutic interchange guidelines and their implementation in hospitals and ambulatory care settings.

Authors:  Maria Adrover-Rigo; Maria-Dolores Fraga-Fuentes; Francesc Puigventos-Latorre; Iciar Martinez-Lopez
Journal:  Eur J Clin Pharmacol       Date:  2018-10-19       Impact factor: 2.953

4.  Medication and Treatment Adherence Following Hospital Discharge.

Authors:  Claudia Greißing; Peter Buchal; Hans-Joachim Kabitz; Marcus Schuchmann; Niko Zantl; Susanne Schiek; Thilo Bertsche
Journal:  Dtsch Arztebl Int       Date:  2016-11-04       Impact factor: 5.594

Review 5.  [Patient safety based on computer-assisted drug therapy. Electronic check-up of the patient].

Authors:  T Bertsche; J Kaltschmidt; W E Haefeli
Journal:  Internist (Berl)       Date:  2009-06       Impact factor: 0.743

6.  Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care.

Authors:  Markus G Pruszydlo; Stefanie U Walk-Fritz; Torsten Hoppe-Tichy; Jens Kaltschmidt; Walter E Haefeli
Journal:  BMC Med Inform Decis Mak       Date:  2012-11-27       Impact factor: 2.796

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.